ArticleFrontiers in neurology2017
Alopecia Universalis following Alemtuzumab Treatment in Multiple Sclerosis: A Barely Recognized Manifestation of Secondary Autoimmunity-Report of a Case and Review of the Literature.
Article in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women.Archives of dermatological research · 2023Article
- Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor.Journal of inflammation research · 2023Article
- Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.Journal of central nervous system disease · 2022Article
- Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients.International journal of environmental research and public health · 2021Review
- Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.Journal of neurology · 2021Review
- Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Ocrelizumab-induced alopecia areata-A series of five patients from Ontario, Canada: A case report.SAGE open medical case reports · 2020Article
- Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.Drug safety · 2019Review
- Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.EBioMedicine · 2019Article
- Case of alemtuzumab-related alopecia areata management in MS.Neurology(R) neuroimmunology & neuroinflammation · 2019Article
- Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.Therapeutics and clinical risk management · 2019Article
- Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.Frontiers in neurology · 2019Review
- Pulsed immune reconstitution therapy in multiple sclerosis.Therapeutic advances in neurological disorders · 2019Review
- Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice?Neurology and therapy · 2018Article
- Article
- Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary autoimmunity is the most frequent adverse event occurring in almost every other alemtuzumab-treated multiple sclerosis patient. We report a case of a patient with relapsing-remitting multiple sclerosis who reported smooth, circular areas of complete hair loss on both thighs 6 months after the second treatment cycle with alemtuzumab. The patient was diagnosed as having alopecia areata (AA). Within 3 months, AA progressed to complete loss of all body hair (alopecia universalis). Current literature rarely connects alemtuzumab with the onset of alopecia of autoimmune origin. Here, we report a little-noticed autoimmune disease affecting the skin, very likely being associated with alemtuzumab. We emphasize the necessity of careful clinical surveillance of alemtuzumab-treated patients for yet undescribed autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.